4507
Shionogi & Co., Ltd.
2026/04/02
Completed the transfer of rights for the Edaravone business from Tanabe Pharma effective April 1, 2026, and established the Radicava business company. Annual sales revenue of approximately 700 million USD expected from fiscal year 2026.
